demonstrated anti-CEA-CAR NK-92MI cells in a CEA-dependent manner recognized and lysed high CEA-expressing tumor cells (215, 216) and NKG2D CAR mRNA-engineered NK cells significantly improved the cytolytic activity of NK cells against tumors (217). The gene discussed is KLRK1; the disease is neoplasm.